Using metal ion-linked nanostructures to improve immune response and boost breast tumor treatment

Immune checkpoint blockade (ICB) is one of the primary methods of tumor immunotherapy. However, clinical data have shown that only a portion of patients respond to ICB treatment. Since the tumor's immune-suppressive environment plays a crucial role in ICB therapy, finding ways to effectively reshape this environment and increase the response rate to ICB treatment has become a key focus.